Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Esperion (NASDAQ: ESPR) will report Q4 and full-year 2025 financial results before the market opens on Tuesday, March 10, 2026. Management will host a live audio webcast at 8:00 a.m. ET to discuss results and business updates.
Webcast access and a replay will be available on the company's investor site, with the replay archived for approximately 90 days.
Details
News Market Reaction – ESPR
On Feb 24, the day this news came out, ESPR closed 1.20% below the previous close.
Data tracked by StockTitan Argus for the Feb 24 session.
Key Figures
- Earnings date
- March 10, 2026
- Q4 and full year 2025 results scheduled before market open
- Webcast time
- 8:00 a.m. ET
- Management webcast to discuss Q4 and full year 2025 results
- Replay availability
- ≈2 hours after call
- Earnings webcast replay timing
- Replay archive period
- ≈90 days
- Length of time webcast replay remains on company website
- Marketed therapies
- 2 oral therapies
- Non-statin LDL-C therapies currently marketed by Esperion
- Global approvals
- >40 countries
- Countries with approvals for Esperion’s LDL-C therapies
Historical Context
-
Announcement of presentation at 2026 Citizens Life Sciences Conference.
-
Settlement limiting generic entry for NEXLETOL and NEXLIZET until 2040.
-
Grant of 40,200 RSUs to new employees under inducement plan.
-
Preliminary 2025 results and long-term Vision 2040 growth strategy.
-
Planned presentation at the 44th Annual J.P. Morgan Healthcare Conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cardiometabolic medical
rare/orphan disease medical
low-density lipoprotein cholesterol (LDL-C) medical
ACLY biology medical
renal diseases medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.
A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.
With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.